We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-19.07%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$129M
AUM Growth
-$22M
Cap. Flow
-$11.1M
Cap. Flow %
-8.62%
Top 10 Hldgs %
47.53%
Holding
65
New
8
Increased
16
Reduced
26
Closed
13
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$3.31M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.19M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.82M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$994K
5
SDS icon
ProShares UltraShort S&P500
SDS
+$967K

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$10.7M
2
GILD icon
Gilead Sciences
GILD
+$2.74M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$1.5M
4
XNCR icon
Xencor
XNCR
+$1.32M
5
AMGN icon
Amgen
AMGN
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 73.12%
2 Miscellaneous 26.17%
3 Real Estate 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PCRX icon
26
Pacira BioSciences
PCRX
$1.45B
$1.86M 1.44%
35,110
+16,000
+84% +$936K
2015 Q1
4 quarters
VCEL icon
27
Vericel Corp
VCEL
$2.06B
$1.75M 1.35%
298,941
-33,216
-10% -$93.1K
2014 Q4
5 quarters
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$1.44M 1.11%
75,000
+25,000
+50% +$529K
2014 Q4
5 quarters
HOLX icon
29
DELISTED
Hologic
HOLX
$1.33M 1.03%
38,700
-9,300
-19% -$324K
2014 Q4
5 quarters
MDCO
30
DELISTED
Medicines Co
MDCO
$1.29M 1%
40,500
+15,500
+62% +$506K
2015 Q4
1 quarter
LOXO
31
DELISTED
Loxo Oncology, Inc
LOXO
$984K 0.76%
36,000
-24,000
-40% -$502K
2015 Q4
1 quarter
ONCE
32
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$930K 0.72%
+31,500
New +$994K
2016 Q1
0 quarters
SNR
33
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$927K 0.72%
+90,000
New +$843K
2016 Q1
0 quarters
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$1.47B
$855K 0.66%
+13,500
New +$883K
2016 Q1
0 quarters
SDS icon
35
ProShares UltraShort S&P500
SDS
$355M
$853K 0.66%
+450
New +$967K
2016 Q1
0 quarters
ADMS
36
DELISTED
Adamas Pharmaceuticals
ADMS
$781K 0.6%
54,000
-26,000
-33% -$438K
2015 Q4
1 quarter
ACHN
37
DELISTED
Achillion Pharmaceuticals
ACHN
$764K 0.59%
99,000
-1,000
-1% -$7.32K
2014 Q4
5 quarters
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$763K 0.59%
69,109
+12,321
+22% +$122K
2014 Q4
5 quarters
MACK icon
39
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$753K 0.58%
11,439
-4,131
-27% -$216K
2014 Q4
5 quarters
PRTK
40
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$683K 0.53%
45,000
-15,000
-25% -$229K
2015 Q4
1 quarter
MCRB icon
41
Seres Therapeutics
MCRB
$24.3M
$645K 0.5%
1,215
-435
-26% -$227K
2015 Q4
1 quarter
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$630K 0.49%
68,130
-27,570
-29% -$276K
2015 Q1
4 quarters
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$579K 0.45%
108,000
+8,000
+8% +$50.5K
2015 Q4
1 quarter
RXDX
44
DELISTED
Ignyta, Inc.
RXDX
$548K 0.42%
81,000
-19,000
-19% -$156K
2015 Q4
1 quarter
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$533K 0.41%
12,600
-4,400
-26% -$224K
2015 Q3
2 quarters
EYPT icon
46
EyePoint Inc
EYPT
$259M
$482K 0.37%
+18,000
New +$569K
2016 Q1
0 quarters
KPTI icon
47
Karyopharm Therapeutics
KPTI
$7.14M
$442K 0.34%
3,300
-700
-18% -$77.3K
2015 Q3
2 quarters
UTHR icon
48
United Therapeutics
UTHR
$23.2B
$429K 0.33%
3,848
-2,666
-41% -$337K
2014 Q4
5 quarters
LAB icon
49
Standard BioTools
LAB
$248M
$363K 0.28%
45,000
-25,000
-36% -$180K
2015 Q3
2 quarters
LABU icon
50
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$551M
$329K 0.25%
+599
New +$379K
2016 Q1
0 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2016 Portfolio in Review

As of Q1 2016, Opus Point Partners Management held 65 positions worth $129M, down 15% from $151M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $11.1M in Q1 2016, closing 13 positions and reducing 26 holdings. Its most notable exit was iShares Biotechnology ETF, an estimated $10.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Pfizer worth $3.26M.

  • Opus Point Partners Management's largest Q1 2016 buy was Pfizer: 115,940 shares worth $3.26M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2016, an estimated $2.19M increase.
  • Opus Point Partners Management's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $2.74M.
  • Opus Point Partners Management fully exited iShares Biotechnology ETF in Q1 2016, selling an estimated $10.7M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $129M portfolio in Q1 2016.
  • Opus Point Partners Management opened 8 new positions and closed 13 in Q1 2016.
  • Opus Point Partners Management's portfolio value fell 15% quarter-over-quarter to $129M.

Based on Opus Point Partners Management's 13F filing for Q1 2016, filed 13 May 2016.